{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:35:00Z","timestamp":1791394500209,"version":"4.3.3"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jns-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.jns.2016.01.046","type":"journal-article","created":{"date-parts":[[2016,1,22]],"date-time":"2016-01-22T02:47:46Z","timestamp":1453430866000},"page":"266-271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"special_numbering":"C","title":["Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: A phase III, open-label study"],"prefix":"10.1016","volume":"362","author":[{"given":"Yukio","family":"Ando","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Sekijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konen","family":"Obayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuharu","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Misumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyuki","family":"Machii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami","family":"Takata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sh\u00fb-ichi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2016.01.046_bb0005","unstructured":"Coutinho P, Martins da Silva A, Lopes Lima J, Resende Barbosa A. Forty years of experience with type I amyloid neuropathy. Review of 483 cases. In: Glenner GG, Pinho e Costa P, Falcao de Freitas A, editors. Amyloid and amyloidosis. Amsterdam: Excerpta Medica; c1980; p. 88\u201398."},{"key":"10.1016\/j.jns.2016.01.046_bb0010","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jns.2008.02.019","article-title":"Epidemiology of familial amyloid polyneuropathy in Japan: identification of a novel endemic focus","volume":"270","author":"Kato-Motozaki","year":"2008","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2016.01.046_bb0015","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1474-4422(11)70246-0","article-title":"Familial amyloid polyneuropathy","volume":"10","author":"Plant\u00e9-Bordeneuve","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2016.01.046_bb0020","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1750-1172-8-31","article-title":"Guideline of transthyretin-related hereditary amyloidosis for clinicians","volume":"8","author":"Ando","year":"2013","journal-title":"Orphanet. J. Rare Dis."},{"key":"10.1016\/j.jns.2016.01.046_bb0025","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1111\/j.1742-4658.2007.05712.x","article-title":"Transthyretin and familial amyloidotic polyneuropathy. recent progress in understanding the molecular mechanism of neurodegeneration","volume":"274","author":"Hou","year":"2007","journal-title":"FEBS J."},{"key":"10.1016\/j.jns.2016.01.046_bb0030","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1749-6632.1984.tb13742.x","article-title":"Family studies of the genetic abnormality in transthyretin (prealbumin) in Portuguese patients with familial amyloidotic polyneuropathy","volume":"435","author":"Saraiva","year":"1984","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jns.2016.01.046_bb0035","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/nrcardio.2010.67","article-title":"Transthyretin-related amyloidoses and the heart: a clinical overview","volume":"7","author":"Rapezzi","year":"2010","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.jns.2016.01.046_bb0040","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/archneur.62.7.1057","article-title":"Transthyretin-related familial amyloidotic polyneuropathy","volume":"62","author":"Ando","year":"2005","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2016.01.046_bb0045","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/archneur.59.11.1771","article-title":"Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form","volume":"59","author":"Koike","year":"2002","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2016.01.046_bb0050","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/jnnp-2014-308724","article-title":"Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments","volume":"86","author":"Sekijima","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2016.01.046_bb0055","doi-asserted-by":"crossref","first-page":"9629","DOI":"10.1073\/pnas.1121005109","article-title":"Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade","volume":"109","author":"Bulawa","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jns.2016.01.046_bb0060","series-title":"Vyndaqel, tafamidis \u2014 EPAR summary for the public","author":"European Medicines Agency","year":"2013"},{"key":"10.1016\/j.jns.2016.01.046_bb0065","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s40265-014-0260-2","article-title":"Tafamidis: a review of its use in familial amyloid polyneuropathy","volume":"74","author":"Scott","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.jns.2016.01.046_bb0070","unstructured":"Pharmaceuticals and Medical Devices Agency J. [cited 2015, Feb 4]. Available from: http:\/\/www.pmda.go.jp\/english\/service\/pdf\/drugs\/vyndaqel_sep2013_e.pdf"},{"key":"10.1016\/j.jns.2016.01.046_bb0075","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2016.01.046_bb0080","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1007\/s00415-013-7051-7","article-title":"Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy","volume":"260","author":"Coelho","year":"2013","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2016.01.046_bb0085","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s12265-013-9512-x","article-title":"Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis","volume":"6","author":"Merlini","year":"2013","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"10.1016\/j.jns.2016.01.046_bb0090","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1212\/WNL.49.1.229","article-title":"Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester diabetic neuropathy study cohort","volume":"49","author":"Dyck","year":"1997","journal-title":"Neurology"},{"issue":"Suppl. 2","key":"10.1016\/j.jns.2016.01.046_bb0095","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.2337\/diab.46.2.S5","article-title":"Approaches to improve epidemiological studies of diabetic neuropathy: insights from the Rochester Diabetic Neuropathy Study","volume":"46","author":"Dyck","year":"1997","journal-title":"Diabetes"},{"key":"10.1016\/j.jns.2016.01.046_bb0100","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/mus.10320","article-title":"Individual attributes versus composite scores of nerve conduction abnormality: sensitivity, reproducibility, and concordance with impairment","volume":"27","author":"Dyck","year":"2003","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2016.01.046_bb0105","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.2337\/diacare.28.9.2192","article-title":"Monotonicity of nerve tests in diabetes: subclinical nerve dysfunction precedes diagnosis of polyneuropathy","volume":"28","author":"Dyck","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jns.2016.01.046_bb0110","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1089\/dia.2005.7.497","article-title":"The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy","volume":"7","author":"Vinik","year":"2005","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.jns.2016.01.046_bb0115","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2796.1994.tb01106.x","article-title":"Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy","volume":"235","author":"Suhr","year":"1994","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.jns.2016.01.046_bb0120","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/jnnp-2011-301299","article-title":"Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas","volume":"83","author":"Koike","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2016.01.046_bb0125","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/jcpt.12145","article-title":"Recent progress in the understanding and treatment of transthyretin amyloidosis","volume":"39","author":"Sekijima","year":"2014","journal-title":"J. Clin. Pharm. Ther."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X16300466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X16300466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,15]],"date-time":"2018-09-15T21:54:58Z","timestamp":1537048498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X16300466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":25,"alternative-id":["S0022510X16300466"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2016.01.046","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: A phase III, open-label study","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2016.01.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}